Uncategorized

Final psychedelics guidance suggests FDA is ‘receptive’ to helping companies succeed

Published

on

The agency’s finalized recommendations for clinical testing of psychedelic compounds for mental health could pave the way for companies like Compass Pathways, whose psilocybin-based therapy for treatment-resistant depression could win approval as early as this year.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version